{"name":"Hutchison Medipharma Limited","slug":"hutchison-medipharma-limited","ticker":"","exchange":"","domain":"hutchisonmedipharma.com","description":"Hutchison Medipharma Limited is a biopharmaceutical company focused on the discovery and development of innovative cancer therapies. The company has a robust pipeline with several drugs in various stages of clinical trials, including Anti-PD-1/L1 in Phase 2 and HMPL-523 in Phase 3.","hq":"Hong Kong","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"HMPL-306","genericName":"HMPL-306","slug":"hmpl-306","indication":"Cholangiocarcinoma with FGFR2 fusion or rearrangement","status":"phase_3"},{"name":"HMPL-523","genericName":"HMPL-523","slug":"hmpl-523","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"},{"name":"Savolitinib + Osimertinib","genericName":"Savolitinib + Osimertinib","slug":"savolitinib-osimertinib","indication":"EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance","status":"phase_3"},{"name":"Surufatinib plus Toripalimab","genericName":"Surufatinib plus Toripalimab","slug":"surufatinib-plus-toripalimab","indication":"Advanced or metastatic neuroendocrine tumors (NET)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"HMPL-653","genericName":"HMPL-653","slug":"hmpl-653","indication":"Other","status":"phase_1"},{"name":"Volitinib","genericName":"Volitinib","slug":"volitinib","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"HMPL-306","genericName":"HMPL-306","slug":"hmpl-306","phase":"phase_3","mechanism":"HMPL-306 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["Cholangiocarcinoma with FGFR2 fusion or rearrangement","Other FGFR-altered solid tumors"],"catalyst":""},{"name":"HMPL-523","genericName":"HMPL-523","slug":"hmpl-523","phase":"phase_3","mechanism":"HMPL-523 is a selective inhibitor of focal adhesion kinase (FAK) that disrupts tumor cell adhesion and migration signaling.","indications":["Advanced solid tumors (Phase 3 development)","Non-small cell lung cancer (NSCLC)"],"catalyst":""},{"name":"HMPL-653","genericName":"HMPL-653","slug":"hmpl-653","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Savolitinib + Osimertinib","genericName":"Savolitinib + Osimertinib","slug":"savolitinib-osimertinib","phase":"phase_3","mechanism":"Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.","indications":["EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance"],"catalyst":""},{"name":"Surufatinib plus Toripalimab","genericName":"Surufatinib plus Toripalimab","slug":"surufatinib-plus-toripalimab","phase":"phase_3","mechanism":"Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.","indications":["Advanced or metastatic neuroendocrine tumors (NET)","Advanced hepatocellular carcinoma"],"catalyst":""},{"name":"Volitinib","genericName":"Volitinib","slug":"volitinib","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxOZTUxa1M3azk0c0NhUTNFbWdURURuY3FKU2MzSHJtRWdSeXRFbjh4a1FMb0pQV3F4YlBkYmRfZXJYSE9UOW9ab3JuY2h3d084NmpFUjNPMVJoVWVnX05FbU5lMXRqMWY5dXNxcGdJNHRsMHlIcU83NnhiTGJ5dEVFRjJaWFhkQXRQcUJtTk5EOTM2X0Jkc0FEQ1AzcTk3YklMYXlJczlhSGFDR09EODJiN3FZLUE4Q09LNE1EN0Qwck4xeXk2Qk1KUHpTaUlmQVZ4TDJWWlhyRmRjd2hNTmhRYkdzWW9LVElzbkhTTVZ1WGRnOWJpM25vOGlEakJJaWpiN2RlVEZwX0dVQS1qZ3o2MWpVWnJKeXV4WkZxVndrQ1NrVkttVHliNWNOano0dnBWRmpOMEtWbk4yS29qNzlvTg?oc=5","date":"2026-04-02","type":"pipeline","source":"GlobeNewswire","summary":"Metastatic Lung Adenocarcinoma Treatment Market Outlook - GlobeNewswire","headline":"Metastatic Lung Adenocarcinoma Treatment Market Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQVlRkTll3MTFwUmw2M25SeXdYSkxRd2JSZnhSQXhJSzhBb09RblViLVlJR2ZzbHktZnpLaEpRdkdITVBJOExRVkptR19tVmFHZ2p0YVlSeXlLa2o2cGxvYUFnTGpqZkFodlM0SUVFN3hqMUlyUncwWW9CNWt6NElmRHZScUN4cnBrLUNoMk1OajZRNG1uSFRKVmlBbmJSOG9TeF83VmstWWthV0NVMlhoUXpDbC1KeVBYMXgzeGJCd01Nb0xTVHJvQVVOZGxSY2xSMUozQnlBdTcxNHIxVGl4S2FLdzA5b3daM20zcmEyb1czVjhtbW1QOGVKY1QydEdBSzVDOFhYLVlQTkFMdUNyWFI0cmhSYmVOYkljNGZR?oc=5","date":"2026-03-02","type":"regulatory","source":"PR Newswire","summary":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxQRVdUS0swLVFUUE92SGNCUWd6VGMzNHE4TGpuYWVVWmRWb3pDYmM5NDd3Mm9WSm95dTctblA1bkRkVmRYYTl1bDIyVHJSX2UyeFFzY2lnbzZOYW9HMTdVY21vWHhPa3lXckhnS3NWZHRDa25hMFppUHJvZ3FXSXFoQzlQQWp6czNEV3ZjNmdCc0xuMGREVjlveE1fS0xsWGJzNjNEaXFmS1VlOFBPTjV2LWZDOUk3OVpLMXN2b1RDd0xoWnV5YkZCQnEyY2F6eUx3SEpCZnZVLUN0bmxHcWxUdUduRS1wMGJqSkhHbTdBbmZjQW11TnY2MnlZR3AyMnk5RVdfdWxPWVlKZ2hOWUhnaF9iVWpLZnBHTnVRS1BLd3BsSGhLamVRMWVmQzU3M01hajVkOTBVcEo?oc=5","date":"2025-06-19","type":"pipeline","source":"PR Newswire","summary":"Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline | DelveInsight - PR Newswire","headline":"Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOTk5qZW1sUDFQOEtFdmY0V2ZVS0hEZ3lXQXY2SlFQektZTW84ZmE0VWZaRUZOenJUWUVVZUxmbFU1N052U0MwY2hVMzJqR2xNVjB0WmF6UGpuWnd3ZUZYYURocllSa3RWVXhfbnRlZVpHenRoQjNVYnRwUzcwdG83U0p0UWR2QVpwMENNRzdicEh4WGZLeXR3QVpGZHdvbWFzN1RzMjg1NHgzVXBfZHl2SUNSVW5Ycl9YTUlvcHRfTmFmaXlNSHJtMWkyQ1MxaEVYZW44X0VQbGluN21jbENrSUFvOGJxOG1RSmtGUmZvbHFiU1F3aTd3dkU4LUhMNEpocmZ5RDdB?oc=5","date":"2025-03-04","type":"pipeline","source":"IANS","summary":"Indo-Asian News Service - IANS","headline":"Indo-Asian News Service","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZXRadHh1QVBTN0xSZ3gySm13Wk43N0FnQ0JBaXpEY2pSRG1RTmh6N0pZUGxrS2lGQWZGOXhTVVE4UXJZdzBtLXdnSmdWQnVhajcwQkMxNkJ0cWttSnNVd3NfYm52OUt0NXRnUE9FUDZWaFhpYWlfVy1BWGloWTFNeG5TQzNDenlQT3Nnd3RGeUxWUlNZUUZRVklIY0RkQQ?oc=5","date":"2024-12-03","type":"pipeline","source":"openPR.com","summary":"Warm Autoimmune Hemolytic Anemia WAIHA Market Sector Analysis, - openPR.com","headline":"Warm Autoimmune Hemolytic Anemia WAIHA Market Sector Analysis,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxORmREbWNJelp6ZXlnLXdmRHoxSTZtMThKUjE2b01fV2NOR05ZdWhJcENIOEtDakZLOTNJS0sxRVpyZDN3eEg4bzgtNzVlTjloeEhOcE82aE84WmMwME5lYXktZXNHSlJseTQteTFGVmRaMFNqbmx1T2hQcFNIMDhHbnhTek9kZWh6NFVWb2RLeUY4RUhwV0VZd3NmLW5rdWZkZUplZUR0UkF1ODVIVW9IM2NuS05qSEFUV0p1bHpjNkN6UVdCSnlqV0lhVGdKYVlmZHJUbW9aclVpLWVEVHFCSFZWSWQzdkQ4NjlKU29FOTVuXzA0d0RrbQ?oc=5","date":"2023-11-21","type":"trial","source":"PR Newswire","summary":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - PR Newswire","headline":"Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNTmtpYURaVEhPYkNqc0FkczdWaHNyQXpkVXRSaVRUT0RDTm42bDQ1N1d3eDh6ZXd6czdkVGdPak5IbGxaekROMEduQnJ2LUdzMFJpbTNyVlRuVDBQMmxHbFZFTlBOS3JvbkgwMVYxSEJnenNnU0dvaF9yUDMtTmxjcXVMeWRxX1hMZ3hTcXdVdFpGM0tUYjFmdHIxbDh4OE5iTVlBQ3Q4V2JyY0g1cWpnZmdzV21yMktObTJNMmY3X2FBQ2R0aXBKbEtOOElkdS1iSnd3SGNRWHNlYzdVT3VBTkh4cklVU0dsaWF2dlhmUnZKNmRBLUplLVhpSm8tODJnNVdHVWlxQUR3U1ZIRVFxYVdPczVMSXhxOGc?oc=5","date":"2023-05-10","type":"pipeline","source":"PR Newswire","summary":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsight - PR Newswire","headline":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBBVFhWZ0tHbWZySGFOaWR5UEU1ci1wTTdlM3RYU3hyVWJoSGdsRkRqTkZZeGVfYUR6VUotSXdjU0JFc21ZaGl0RW5GWFJyakVfRnU2NVo4RFpBQXdkRlQ0ZjVCZEFFOWxDVUcwSXFpbXlnRlpENU90TTh6LWU?oc=5","date":"2018-12-03","type":"pipeline","source":"statnews.com","summary":"Pharma Valley, China’s equivalent of Kendall Square, is expanding rapidly - statnews.com","headline":"Pharma Valley, China’s equivalent of Kendall Square, is expanding rapidly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSWd5Y0NKU3BKQTVPWkp6djFqcUVLaE15ZElhNHFEYkhTc0xxRlpfbzFnY3QyUFZ2S3VlMWE3TU4tYndGTzRhNUtKREt6T3c0YkY0RldTbzlIcEVraFVMQTZ2TExUR2gwZGlndTlRWXlhWVo5YTJKNjQ2eS1NUU84MzZfQThiRHVMZnJwdmtiTmZPemlDcUpXeDdLWl9mYWZFVUU4aC1fVHpNemNSWkJaeXJ1TUl1Und4elJqazBHcTQ?oc=5","date":"2018-09-06","type":"regulatory","source":"BioSpectrum Asia","summary":"Hutchison MediPharma receives approval of Fruquintinib capsules in China - BioSpectrum Asia","headline":"Hutchison MediPharma receives approval of Fruquintinib capsules in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPRkY5blk1ODJrOWlJZXNvdFNYYWdFVjEwOEdMTmVTR0NLNmZ2d1cyMXIyWGp1dkZrczRxekZ6MXJzeXhfTER3SlJybmp3YU9LZ1JCbmJZNVFtdG9zOXNOZEVmTHVsYmNkeUprM1RiVF9XZjM1MGJWMGtLMWpzZWN4QXVnazBGNEtoLWZEQlY5TWNNU1dTVnhzVFhDTTFLdXpFRENBMA?oc=5","date":"2013-04-22","type":"pipeline","source":"Asian Scientist Magazine","summary":"Eli Lilly’s Elanco Invests US$100m In China Animal Healthcare - Asian Scientist Magazine","headline":"Eli Lilly’s Elanco Invests US$100m In China Animal Healthcare","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":4,"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}